Regeneron announced it will discontinue development of bbT369, a CAR‑T candidate acquired from 2seventy bio, halting plans to advance the asset into a planned phase II study. The company described the move as a strategic business decision and said it will not pursue future development of the program. The cut comes amid a broader retrenchment in the cell therapy sector and highlights the selective portfolio choices large biopharma are making as they weigh the modality’s technical and commercial challenges.